Treats angina pectoris due to coronary artery disease. ANDA 75037, held by Genus. Isosorbide Mononitrate.
As of Nov 16, 2026, ANDA 75037 (Isosorbide Mononitrate), held by Genus, was first approved by FDA on Oct 30, 1998, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Isosorbide mononitrate tablets, USP are indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 1998 | Original application | Approved |
| Isosorbide Mononitrate20MG · tablet;oral | Isosorbide Mononitrate | Rx |
| Isosorbide Mononitrate10MG · tablet;oral | Isosorbide Mononitrate | Rx |
| Nov 2, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Apr 17, 2000 | Supplement 2Labeling | Approved | None posted |
| Nov 24, 1999 | Supplement 1Labeling | Approved | None posted |
| Oct 30, 1998 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters